



GODAVARI DRUGS LIMITED

Regd. Off.: 'Mayfair', S.P. Road, Secunderabad - 500 003. TS, India.

14.11.2023

To,
The Manger [Listing]
The BSE Limited
The Secretary, Listing Department
Phirozejeeebhoy Towers,
Dalal Street, Fort,
Mumbai- 400001
Scrip code: 530317

Dear Sirs/Madam,

Sub: Outcome of the Board Meeting of Godavari Drugs Limited (the Company) held on Tuesday 14th November, 2023

Ref: Reg. 30 read with Reg. 33 of SEBI (LODR) Regulations, 2015

We wish to inform you that the Board of Directors of the Company at their meeting held on today, i.e. November 14, 2023 has, inter alia, transacted the following business:

1. Considered and approved the un-audited Financial Results for the quarter and half year ended 30th September, 2023 with limited review report as recommended by the Audit Committee and reviewed by the Statutory Auditors.,
2. The Board discussed and approved the offer letter and to release Rs. 48.89 lacs as earnest money to Maharashtra Industrial Development Corporation (MIDC) for lease of land on long term at Plot No. C-8, Kushnoor Industrial Area, Nanded, Maharashtra, spanning 71,114.00 square meters

The Board Meeting Commenced at 03:45 P.M and concluded at 04:40 PM

A Copy of said results together with the limited review report is enclosed herewith for the Second quarter and half year ended September 30, 2023 are enclosed herewith.

These are also made available on the website of the company at www.godavaridrugs.com

This is for your information and records.

Thanking You,
For Godavari Drugs Limited

Venkatesh Achanta
Company Secretary & Compliance Officer
Membership Number : A53326

GODAVARI DRUGS LIMITED

CIN NO. L24230TG1987PLC008016

Regd. Office : - "Mayfair", S.P.Road, Secunderabad.

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2023

(Rs. In Lakhs)

Sl. No.	Particulars	Quarter ended			Half Year Ended		Year ended
		30.09.2023	30.06.2023	30.09.2022	30.09.2023	30.09.2022	31.03.2023
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	3954.25	3541.88	4054.71	7496.13	8309.71	15962.48
2	Other Income	0.35	45.21	13.20	45.56	19.88	65.53
3	Total Revenue from operations (1+2)	3954.60	3587.09	4067.91	7541.69	8329.59	16028.01
4	Expenses						
	(a) Cost of materials consumed	3035.42	2644.34	3662.06	5679.76	7551.69	13782.07
	(b) Changes in inventories of finished goods & work-in-progress	40.27	162.33	-371.12	202.60	-838.24	-976.30
	(c) Employee benefits expense	119.06	121.95	113.93	241.01	230.71	484.04
	(d) Depreciation & amortization expense	49.38	47.38	47.25	96.76	93.35	194.35
	(e) Finance Costs	129.81	110.98	105.69	240.79	179.87	392.73
	(f) Other Expenses	453.23	388.39	393.06	841.62	868.62	1680.59
	Total expenses	3827.17	3475.37	3950.89	7302.54	8086.00	15557.48
5	Profit before exceptional Items and tax (3-4)	127.43	111.72	117.02	239.15	243.59	470.53
6	Exceptional items						22.95
7	Profit before Tax (5-6)	127.43	111.72	117.02	239.15	243.59	493.48
8	Tax expense	(41.85)	(30.68)	(30.63)	(72.53)	(65.03)	(114.89)
9	Net Profit for the period (7-8)	85.58	81.04	86.39	166.62	178.56	378.58
10	Other Comprehensive Income						
	Items that will not be reclassified to profit or loss						
	(i) loss						
	Income tax relating to Items that will not be reclassified to profit or loss						
	(ii) loss						
	Items that will be reclassified to profit or loss						
	(iii) loss						
	Income tax relating to Items that will be reclassified to profit or loss						
	(iv) loss						
11	Total Comprehensive Income (9+10)	85.58	81.04	86.39	166.62	178.56	378.58
12	Paid-up equity share capital (Face Value Rs. 10/- per share)	753.05	753.05	753.05	753.05	753.05	753.05
13	Other Equity(Reserves and Surplus)						2588.67
14	Earnings per share (of Rs.10/- each) (not annualized)						
	(a) Basic	1.14	1.08	1.15	2.21	2.37	5.03
	(b) Diluted	1.14	1.08	1.15	2.21	2.37	5.03

Notes:

- The above results, as reviewed by the Audit Committee, were considered, approved and taken on record by the Board of Directors at its meeting held on 14th November 2023
- The above results were prepared in accordance with Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable
- The Limited Review by the Statutory Auditors for the quarter ended as required under regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been received.
- Corresponding figures in previous year / period have been regrouped wherever considered necessary.


For GODAVARI DRUGS LIMITED

Mohit Jaju

Mohit Jaju

Whole Time Director/CFO

DIN: 03405414



Place: Secunderabad

Date: 14-11-2023


GODAVARI DRUGS LIMITED
CIN NO.L24230TG1987PLC008016
Regd. Office : - "Mayfair", S.P.Road, Secunderabad.

Statement of Assets and Liabilities

(Rs. In Lakhs)

Particulars	Half Year ended (30.09.2023)	Year ended (31.03.2023)
	(Unaudited)	(Audited)
ASSETS		
1. Non - current assets		
a. Property, plant and equipment	2396.17	2491.00
b. Capital work - in -progress	1335.51	907.53
c. Investment Property		
d. Goodwill		
e. Other Intangible assets		
f. Intangible assets under development		
g. Biological Assets other than bearer plants		
h. Financial Assets		
(i) Investments	0.01	0.01
(ii) Trade Receivables		
(iii) Loans		
(iv) Other Financial Assets	130.82	44.18
i. Deferred tax assets (net)		
j. Other non-current assets		
2. Current assets		
(a) Inventories	1848.01	1985.57
(b) Financial Assets		
(i) Investments		
(ii) Trade Receivables	6368.20	5793.49
(iii) Cash and cash equivalents	249.33	308.46
(iv) Bank balances other than (iii) above		
(v) Loans	88.69	88.75
(vi) Others (to be specified)		
(c) Current Tax Assets (Net)		
(d) Other current assets	300.11	524.30
Total Assets	12716.84	12143.30
EQUITY AND LIABILITIES		
EQUITY		
(a) Equity Share capital	753.05	753.05
(b) Other Equity	2755.29	2588.67
(i) Reserves and surplus		
Non controlling interest		
LIABILITIES		
1. Non - current liabilities		
(a) Financial Liabilities		
(i) Borrowings	1153.00	1194.75
(ii) Trade payables		
(iii) Other financial liabilities (other than those specified in item (b))		
(b) Provisions	70.18	71.43
(c) Deferred tax liabilities (Net)	170.34	164.58
(d) Other non-current liabilities		
2. Current liabilities		
(a) Financial Liabilities		
(i) Borrowings	2217.42	2154.88
(ii) Trade payables		
(A) Total outstanding dues of micro enterprise and small enterprise and		
(B) Total outstanding dues creditors other than of micro enterprise and small enterprise		11.99
(iii) Other financial liabilities (other than those specified in item (c))	4930.95	4602.87
(iii) Other financial liabilities (other than those specified in item (c))	599.84	499.41
(b) Other current liabilities		
(c) Provisions		
(d) Current Tax Liabilities (Net)	66.77	101.67
Total Equity and Liabilities	12716.84	12143.30

For GODAVARI DRUGS LIMITED


Monit Laju

Whole Time Director/CFO

DIN: 03405414

Place: Secunderabad

Date : 14.11.2023



Godavari Drugs Limited
Cash Flow Statement for the half year ended September 30,2023


(Rs. In Lakhs)

Particulars		Period ended 30.09.2023	Previous Year 2022-23
A. Cash Flow from Operating Activities			
Profit before Depreciation, Interest and Tax		576.70	1080.55
Other income considered separately		-45.55	-65.53
	Net	531.14	1015.02
(Increase) / Decrease in Inventories		137.56	-982.19
(Increase) / Decrease in Receivables		-574.70	-235.59
(Increase) / Decrease in Short term Loans & Advances		0.06	-27.88
(Increase) / Decrease in Other Current Assets		224.19	59.34
Increase / (Decrease) in Current Liabilities		449.93	1607.91
Less: Income tax paid		-66.77	-101.67
Less: Deferred Tax Adjustment		-5.75	-13.22
	Total A	695.66	1321.71
B. Cash Flow from Investing Activities			
Increase in Fixed Assets and Capital WIP (net)		-429.91	-929.67
Increase in Non Current Assets		-86.64	-10.61
Other Income		45.56	61.60
Sale of retired fixed assets (Scrap)		0.00	14.83
	Total B	-471.00	-863.85
C. Cash Flow from Financing Activities			
Increase / (Decrease) in Long Term Borrowings		-41.75	16.54
Increase / (Decrease) in Long Term Provisions		-1.26	-0.84
Increase / (Decrease) in Long Term Advances		0.00	0.00
Interest Paid		-240.79	-392.73
	Total C	-283.79	-377.03
D. Net Increase/(Decrease) in cash and cash equivalents [A+B+C]		-59.13	80.83
Cash and cash equivalents at the beginning of the year (01.04.2023)		308.46	227.64
Cash and cash equivalents at the end of the year (30.09.2023)		249.33	308.46
Increase/(-)Decrease		-59.13	80.83

For GODAVARI DRUGS LIMITED



Mohit Jaju
Whole Time Director/CFO
DIN: 03405414



Place: Secunderabad
Date : 14.11.2023

**Independent Auditor's Review Report on unaudited quarterly financial results of
Godavari Drugs Limited Pursuant to the Regulation 33 of the SEBI (Listing
Obligations and Disclosure Requirements) Regulations, 2015**


To,
The Board of Directors
Godavari Drugs Limited
Hyderabad

We have reviewed the accompanying statement of unaudited financial results of Godavari Drugs Limited (the Company) for the quarter and half year ended on September, 30, 2023 (the statement). This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ayyadevara & Co.,
Chartered Accountants
FRN: 00278S



Ayyadevara Srinivas
Proprietor
ICAI Membership No. 028803
Hyderabad, Nov 14, 2023.
UDIN: 23028803BGZHKQ1694

